
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4082007/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy. New England Journal of Medicine, 2008, 358, 252-260.	27.0	2,141
2	Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet, The, 2018, 391, 1357-1366.	13.7	2,076
3	Serotonin a la carte: Supplementation with the serotonin precursor 5-hydroxytryptophan. , 2006, 109, 325-338.		266
4	A Circadian Signal of Change of Season in Patients With Seasonal Affective Disorder. Archives of General Psychiatry, 2001, 58, 1108.	12.3	246
5	Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. Focus (American) Tj ETQq1 1	l 0. <b>784</b> 314	rg <b>Ba7/</b> Overic
6	Rethinking recommendations for screening for depression in primary care. Cmaj, 2012, 184, 413-418.	2.0	184
7	Role of serotonin transporter promoter repeat length polymorphism (5-HTTLPR) in seasonality and seasonal affective disorder. Molecular Psychiatry, 1998, 3, 175-177.	7.9	167
8	Treatment of a Rapidly Cycling Bipolar Patient by Using Extended Bed Rest and Darkness to Stabilize the Timing and Duration of Sleep. Biological Psychiatry, 1998, 43, 822-828.	1.3	155
9	Does Publication Bias Inflate the Apparent Efficacy of Psychological Treatment for Major Depressive Disorder? A Systematic Review and Meta-Analysis of US National Institutes of Health-Funded Trials. PLoS ONE, 2015, 10, e0137864.	2.5	153
10	Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications. BMJ: British Medical Journal, 2009, 339, b2981-b2981.	2.3	149
11	Effects of Tryptophan Depletion vs Catecholamine Depletion in Patients With Seasonal Affective Disorder in Remission With Light Therapy. Archives of General Psychiatry, 1998, 55, 524.	12.3	143
12	WHAT IS THE THRESHOLD FOR A CLINICALLY RELEVANT EFFECT? THE CASE OF MAJOR DEPRESSIVE DISORDERS. Depression and Anxiety, 2014, 31, 374-378.	4.1	141
13	Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis. BMJ Open, 2016, 6, e010919.	1.9	139
14	Reporting of Conflicts of Interest in Meta-analyses of Trials of Pharmacological Treatments. JAMA - Journal of the American Medical Association, 2011, 305, 1008.	7.4	121
15	Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. Lancet Psychiatry,the, 2019, 6, 977-979.	7.4	104
16	Reporting Bias in Clinical Trials Investigating the Efficacy of Second-Generation Antidepressants in the Treatment of Anxiety Disorders. JAMA Psychiatry, 2015, 72, 500.	11.0	92
17	Publication Bias in Antipsychotic Trials: An Analysis of Efficacy Comparing the Published Literature to the US Food and Drug Administration Database. PLoS Medicine, 2012, 9, e1001189.	8.4	88
18	Comparison of psychotherapies for adult depression to pill placebo control groups: a meta-analysis. Psychological Medicine, 2014, 44, 685-695.	4.5	86

#	Article	IF	CITATIONS
19	Reporting of Positive Results in Randomized Controlled Trials of Mindfulness-Based Mental Health Interventions. PLoS ONE, 2016, 11, e0153220.	2.5	80
20	Two naturally occurring amino acid substitutions of the 5-HT2A receptor: Similar prevalence in patients with seasonal affective disorder and controls. Biological Psychiatry, 1996, 40, 1267-1272.	1.3	79
21	Effects of Exogenous Melatonin Administration and Withdrawal in Five Patients With Rapid-Cycling Bipolar Disorder. Journal of Clinical Psychiatry, 1997, 58, 383-388.	2.2	75
22	Efficacy of antidepressants. BMJ: British Medical Journal, 2008, 336, 516-517.	2.3	58
23	Publication Bias, with a Focus on Psychiatry: Causes and Solutions. CNS Drugs, 2013, 27, 457-468.	5.9	52
24	Financial Conflicts of Interest Among Oncologist Authors of Reports of Clinical Drug Trials. JAMA Oncology, 2018, 4, 1426.	7.1	52
25	Bimodal patterns of human melatonin secretion consistent with a two-oscillator model of regulation. Neuroscience Letters, 1995, 194, 105-108.	2.1	49
26	Monorhinal odor identification and depression scores in patients with seasonal affective disorder. Journal of Affective Disorders, 1999, 56, 27-35.	4.1	49
27	Patients With Seasonal Affective Disorder Have Lower Odor Detection Thresholds Than Control Subjects. Archives of General Psychiatry, 2002, 59, 1119.	12.3	47
28	A Taxpayer-Funded Clinical Trials Registry and Results Database. PLoS Medicine, 2004, 1, e60.	8.4	46
29	Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. BMJ, The, 2012, 345, e5155-e5155.	6.0	46
30	The Effects of Seasons and Light Therapy on G Protein Levels in Mononuclear Leukocytes of Patients With Seasonal Affective Disorder. Archives of General Psychiatry, 1999, 56, 178.	12.3	44
31	Salivary and plasma measures of dim light melatonin onset (DLMO) in patients with rapid cycling bipolar disorder. Biological Psychiatry, 1996, 40, 731-735.	1.3	43
32	Effects of Leuprolide-Induced Hypogonadism and Testosterone Replacement on Sleep, Melatonin, and Prolactin Secretion in Men. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3203-3207.	3.6	39
33	5-Hydroxytryptophan plus SSRIs for interferon-induced depression: Synergistic mechanisms for normalizing synaptic serotonin. Medical Hypotheses, 2005, 65, 138-144.	1.5	38
34	How to access and process FDA drug approval packages for use in research. BMJ, The, 2013, 347, f5992-f5992.	6.0	38
35	Three-year follow-up of older schizophrenics: Extrapyramidal syndromes, psychiatric symptoms, and ventricular brain ratio. Biological Psychiatry, 1991, 30, 913-926.	1.3	36
36	Platelet [3H]paroxetine binding, 5-HT-stimulated Ca2+ response, and 5-HT content in winter seasonal affective disorder. Biological Psychiatry, 1994, 36, 458-466.	1.3	35

#	Article	IF	CITATIONS
37	Influence of baseline severity on antidepressant efficacy for anxiety disorders: Meta-analysis and meta-regression. British Journal of Psychiatry, 2016, 208, 515-521.	2.8	34
38	Diurnal Variation in the Direction of Mood Switches in Patients With Rapid-Cycling Bipolar Disorder. Journal of Clinical Psychiatry, 1997, 58, 79-84.	2.2	33
39	Seasonality and pituitary volume. Psychiatry Research - Neuroimaging, 1997, 74, 151-157.	1.8	32
40	Seasonal variation in core temperature regulation during sleep in patients with winter seasonal affective disorder. Biological Psychiatry, 1997, 42, 122-131.	1.3	31
41	Serotonin hypothesis of winter depression: behavioral and neuroendocrine effects of the 5-HT1A receptor partial agonist ipsapirone in patients with seasonal affective disorder and healthy control subjects. Psychiatry Research, 1999, 86, 9-28.	3.3	31
42	Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials. PLoS Medicine, 2022, 19, e1003886.	8.4	31
43	Is It Always Unethical to Use a Placebo in a Clinical Trial?. PLoS Medicine, 2005, 2, e72.	8.4	28
44	Ultradian oscillations in cranial thermoregulation and electroencephalographic slow-wave activity during sleep are abnormal in humans with annual winter depression. Brain Research, 2000, 866, 152-167.	2.2	25
45	Hiding negative trials by pooling them: a secondary analysis of pooled-trials publication bias in FDA-registered antidepressant trials. Psychological Medicine, 2019, 49, 2020-2026.	4.5	25
46	Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety: A meta-analysis. European Neuropsychopharmacology, 2016, 26, 1752-1759.	0.7	24
47	Antidepressants might work for people with major depression: where do we go from here?. Lancet Psychiatry,the, 2018, 5, 461-463.	7.4	23
48	Double-Blind, Placebo-Controlled Study of Single-Dose Metergoline in Depressed Patients With Seasonal Affective Disorder. Journal of Clinical Psychopharmacology, 2002, 22, 216-220.	1.4	21
49	A controlled trial of cyanocobalamin (Vitamin B12) in the treatment of winter seasonal affective disorder. Journal of Affective Disorders, 1994, 32, 197-200.	4.1	20
50	Agreement between face-to-face and telephone-administered mood ratings in patients with rapid cycling bipolar disorder. Psychiatry Research, 1997, 71, 129-132.	3.3	20
51	Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. The Cochrane Library, 2021, 2021, CD011612.	2.8	20
52	Greater Improvement in Summer Than With Light Treatment in Winter in Patients With Seasonal Affective Disorder. American Journal of Psychiatry, 1998, 155, 1614-1616.	7.2	19
53	Strategies to Decrease Costs of Prescribing Selective Serotonin Reuptake Inhibitors at a VA Medical Center. Psychiatric Services, 2003, 54, 195-200.	2.0	17
54	Ranking antidepressants. Lancet, The, 2009, 373, 1760.	13.7	17

#	Article	IF	CITATIONS
55	Cognitive Performance in Seasonal Affective Disorder: Pattern Recognition and the Stroop Task. Journal of Nervous and Mental Disease, 1996, 184, 56-59.	1.0	17
56	Effects of Leuprolide-Induced Hypogonadism and Testosterone Replacement on Sleep, Melatonin, and Prolactin Secretion in Men. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3203-3207.	3.6	15
57	Healthcare Options for People Experiencing Depression (HOPE*D): the development and pilot testing of an encounter-based decision aid for use in primary care. BMJ Open, 2019, 9, e025375.	1.9	13
58	An open science pathway for drug marketing authorization—Registered drug approval. PLoS Medicine, 2021, 18, e1003726.	8.4	12
59	Closing a Loophole in the FDA Amendments Act. Science, 2008, 322, 44-46.	12.6	11
60	Reporting of financial conflicts of interest in meta-analyses of drug trials published in high-impact medical journals: comparison of results from 2017 to 2018 and 2009. Systematic Reviews, 2020, 9, 77.	5.3	11
61	Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study. BMJ Open, 2020, 10, e035633.	1.9	8
62	Effect of Season and Light Treatment Upon Hot Flashes in a Perimenopausal SAD Patient. Chronobiology International, 1995, 12, 290-297.	2.0	5
63	Spin in RCTs of anxiety medication with a positive primary outcome: a comparison of concerns expressed by the US FDA and in the published literature. BMJ Open, 2017, 7, e012886.	1.9	5
64	All the relevant data?. BMJ: British Medical Journal, 2010, 341, c6487-c6487.	2.3	5
65	Correction/Clarification about FDA Review Documents. PLoS Medicine, 2005, 2, e422.	8.4	4
66	Novel Treatment Strategies for Depression in Patients With Hepatitis C. Psychosomatics, 2010, 51, 357-358.	2.5	4
67	You can now search FDA approval documents easily at fda.opentrials.net. BMJ: British Medical Journal, 2017, 356, j677.	2.3	4
68	Validation of the hypomania interview guide-seasonal affective disorder (HIGH-SAD) version in patients with rapid cycling bipolar disorder. , 1998, 8, 166-168.		3
69	Network meta-analysis of antidepressants – Authors' reply. Lancet, The, 2018, 392, 1012-1013.	13.7	3
70	Light visor maintenance of light box response. American Journal of Psychiatry, 1997, 154, 1172a-1172.	7.2	2
71	Gender differences in glycosylated hemoglobin levels in seasonal affective disorder patients and controls. Comprehensive Psychiatry, 1999, 40, 234-237.	3.1	2
72	Posting FDA New Drug Application Reviews. JAMA - Journal of the American Medical Association, 2007, 298, 859.	7.4	2

ERICK H TURNER

#	Article	IF	CITATIONS
73	Re-rethinking the article by Thombs and colleagues: Figure 1:. Cmaj, 2012, 184, 438.2-439.	2.0	2
74	Novel Treatment Strategies for Depression in Patients With Hepatitis C. Psychosomatics, 2010, 51, 357-358.	2.5	2
75	The Effect of Funding Source on Outcome Reporting Among Drug Trials. Annals of Internal Medicine, 2011, 154, 137.	3.9	1
76	Approval of esketamine for treatment-resistant depression – Author's reply. Lancet Psychiatry,the, 2020, 7, 236.	7.4	1
77	Author's Reply to Shrier: "Publication Bias, With a Focus on Psychiatry: Causes and Solutions― CNS Drugs, 2013, 27, 775-776.	5.9	0
78	From the FDA, we still hear mostly thunderous silence. BMJ, The, 2015, 351, h3763.	6.0	0